Esomeprazole use in pediatrics

Pediatric Health

Volumn 2, Issue 6, 2008, Pages 687-696

  Tolia, Vasundhara ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Esomeprazole; Extraesophageal syptoms; Gastroesophageal reflux; GERD; Helicobacter pylori; Pediatrics; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; BRONCHODILATING AGENT; CISAPRIDE; CLARITHROMYCIN; CORTICOSTEROID; ESOMEPRAZOLE; LANSOPRAZOLE; MERCAPTAMINE; METOCLOPRAMIDE; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHEST RETRACTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EMOTION; ERADICATION THERAPY; FACE EDEMA; FAMILY RELATION; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PEDIATRICS; PHARMACODYNAMICS; PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SINGLE DRUG DOSE; SOCIAL LIFE; SOMNOLENCE; STOMACH FUNDOPLICATION; THORAX DISEASE; TREATMENT DURATION; WELLBEING; WHEEZING;

EID: 70349637657     PISSN: 17455111     EISSN: None     Source Type: Journal    
DOI: 10.2217/17455111.2.6.687     Document Type: Article

References (46)

1. Katz PO: Medical therapy for gastroesophageal reflux disease in 2007. Rev. Gastroenterol. Disord. 7(4),193-203 (2007).
2. Nelson SP, Chen EH, Syniar GM, Christoffel KK: Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch. Pediatr. Adolesc. Med. 151(6), 569-572 (1997).
3. Rudolph CD, Mazur LJ, Liptak GS et al.: North American Society for Pediatric Gastroenterology and Nutrition. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 32(Suppl. 2), S1-S31 (2001).
4. Sappati Biyyani RS, Chessler L, McCain E, Nelson K, Fahmy N, King J: Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. Dis. Esophagus. 20(1), 53-57 (2007).
5. Crawley J, Tolia V, Illueca M, Barker P, Luo R: Effect of gastroesophageal reflux disease on the activities of daily living of caregivers for young children with gastroesophageal reflux disease after esomeprazole treatment. J. Pediatr. Gastroenterol. Nutr. 45(4), E42, (2007).
6. Galmiche JP: How do we offer clinical relief to patients with gastro-oesophageal reflux disease? Eur. J. Gastroenterol. Hepatol. 12(Suppl. 1), S3-6 (2000).
7. Wang WH, Huang JQ, Zheng GF et al.: Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J. Gastroenterol. 11(26), 4067-4077 (2005).
8. Pai V, Pai N: Recent advances in chirally pure proton pump inhibitors. J. Indian Med. Assoc. 105(8), 469-470, 472, 474 (2007).
9. Zhou Q, Yan XF, Pan WS, Zeng S: Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? World J. Gastroenterol. 14(16), 2617-2619 (2008).
10. Croxtall JD, Perry CM, Keating GM: Esomeprazole: in gastroesophageal reflux disease in children and adolescents. Paediatr. Drugs. 10(3), 199-205 (2008).
11. Boccia G, Manguso F, Miele E, Buonavolontá R, Staiano A: Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am. J. Gastroenterol. 102(6), 1291-1297 (2007).
12. Andersson T, Hassall E, Lundborg P et al.: Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am. J. Gastroenterol. 95(11), 3101-3106 (2000).
13. Kearns GL, Andersson T, James LP et al.: Omeprazole disposition in children following single-dose administration. J. Clin. Pharmacol. 43(8), 840-848 (2003).
14. Gremse D, Winter H, Tolia V et al.: Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 35 (Suppl. 4), S319-S326 (2002).
15. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L: Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J. Pediatr. Gastroenterol. Nutr. 35(Suppl. 4), S308-S318 (2002).
16. Tolia V, Fitzgerald J, Hassall E, Huang B, Pilmer B, Kane R 3rd: Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J. Pediatr. Gastroenterol. Nutr. 35(Suppl. 4), S300-7 (2002).
17. James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J: Study 119 Pediatric Trial Investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin. Ther. 29(9), 2082-2092 (2007).
18. Gilger MA, Tolia V, Vandenplas Y, Youssef NN, Traxler B, Illueca M: Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 46(5), 524-533 (2008).
19. Gold BD. Gunasekaran T, Tolia V et al.: Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 45(5), 520-529 (2007).
20. Tolia V, Gilger MA, Barker PN, Illeuca M: Healing of erosive esophagitis (EE) and improvement in symptoms of gastroesophageal reflux disease (GERD) in 1- and 2-year-old children after esomeprazole treatment. Gastrointest. Endosc. 5(Suppl 1), AB118, Abs 670 (2007).
21. Arenz T, Antos D, Rüssmann H et al.: Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children. J. Pediatr. Gastroenterol. Nutr. 43(2), 180-184 (2006).
22. Xiang L, Wen FQ, Zuo WH, Tang Y: Different courses of esomeprazole-based triple therapy for Helicobactor pylori infection in children. Zhongguo Dang Dai Er Ke Za Zhi 9(3), 205-206 (2007).
23. Dohil R, Fidler M, Barshop B et al.: Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr. Nephrol. 20(12), 1786-1793 (2005).
24. Tolia V, Boyer K: Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig. Dis. Sci. 53(2), 385-393 (2008).
25. Davidson G, Omari T, Haslam R et al.: Acid-suppressive effects and pharmacokinetics after 7 days repeated once-daily dosing of esomeprazole in preterm infants and neonates with pathological acid gastroesophageal reflux. Gastroenterology 132(4 Suppl. 1), A-488, (2007).
26. Omari T, Davidson G, Bondarov P, Nauclér E, Nilsson C, Lundborg P: Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease. J. Pediatr. Gastroenterol. Nutr. 45(5), 530-537 (2007).
27. Zhao J, Li J, Hamer-Maansson JE et al.: Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clinical Therapeutics 28(11), 1868-1876 (2006).
28. Li J, Zhao J, Hamer-Maansson JE et al.: Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. Clinical Therapeutics 28(3), 419-427 (2006).
29. Sostek MB, Chen Y, Andersson T: Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br. J. Clin. Pharmacol. 64(3), 386-390 (2007).
30. Bladh N, Blychert E, Johansson K et al.: A new esomeprazole packet (sachet) formulation for suspension: in vitro characteristics and comparative pharmacokinetics versus intact capsules/tablets in healthy volunteers. Clin. Ther. 29(4), 640-649 (2007).
31. Omari T, Davidson G, Haslam R et al.: Effect of esomeprazole on gastroesophageal reflux measured by 24-h pH-impedance monitoring in preterm infants and neonates with pathological acid gastroesophageal reflux. Gastroenterology 132(4 Suppl. 1), A-485 (2007).
32. Omari T, Davidson G, Haslam R, Bondarov P, Naucler E, Lungborg P: Effect of esomeprazole on acid reflux, volume reflux and reflux symptoms in neonates with gastroesophageal reflux disease. Presented at: The Annual NASPGHAN Meeting. Salt Lake City, UT, USA, 25-57 October, E64 (Abstract 165) (2007).
33. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M: Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 62(10),1503-1538 (2002).
34. Baldassarre E, Sagaon MM, Ferrarini A, Bianchetti MG: Severe systemic adverse reaction to proton pump inhibitors in an infant. Pediatr. Pulmonol. 42(6), 563-564 (2007).
35. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J: Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch. Intern. Med. 167(9), 950-955 (2007).
36. Choudhry MN, Soran H, Ziglam HM: Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 101(6), 445-448 (2008).
37. Canani RB, Cirillo P, Roggero P et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5), E817-E820 (2006).
38. Estborn L, Joelson S: Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf. 31(7), 627-636 (2008).
39. Wright MJ, Proctor DD, Insogna KL, Kerstetter JE: Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr. Rev. 66(2), 103-108 (2008).
40. Kwok A, Lam T, Katelaris P, Leong RW: Helicobacter pylori eradication therapy: indications, efficacy and safety. Expert Opin. Drug Saf. 7(3), 271-281 (2008).
41. Sabbi T, De Angelis P, Dall'Oglio L: Helicobacter pylori infection in children: management and pharmacotherapy. Expert Opin. Pharmacother. 9(4), 577-585 (2008).
42. Aoyama N, Tanigawara Y, Kita T et al.: Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J. Gastroenterol. 34(Suppl. 11), 80-83 (1999).
43. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group: The Montreal definition and classification of gastroesophageal reflux disease: a global, evidence-based consensus. Am. J. Gastroenterol. 101, 1900-1920 (2006).
44. Hunt JF, Gaston B: Airway acidification and gastroesophageal reflux. Curr. Allergy Asthma Rep. 8(1), 79-84 (2008).
45. Khoshoo V, Haydel R Jr: Effect of antireflux treatment on asthma exacerbations in nonatopic children. J. Pediatr. Gastroenterol. Nutr. 44(3), 331-335 (2007).
46. Khoshoo V, Haydel R Jr, Smith M: Spirometry in older children with persistent asthma and gastroesophageal reflux: Before and after antireflux treatment. Pediatr. Asthma Allergy & Immunology 20(1), 6-10 (2007).